Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung CancerAlice T. Shaw, A. John Iafrate, Geoffrey I. Shapiro et al.|New England Journal of Medicine|2014Cited by 2k
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 studyD. Ross Camidge, Alice T. Shaw, Yung‐Jue Bang et al.|The Lancet Oncology|2012Cited by 1.3k
Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement.Alice T. Shaw, Sai‐Hong Ignatius Ou, D. Ross Camidge et al.|Journal of Clinical Oncology|2012Cited by 129
Efficacy and safety of crizotinib in patients with advanced <i>ROS1</i>-rearranged non-small cell lung cancer (NSCLC).Sai‐Hong Ignatius Ou, Alice T. Shaw, Yung‐Jue Bang et al.|Journal of Clinical Oncology|2013Cited by 62